Overview

Extension From Weekly to Once Every Other Week Darbepoetin Alfa Administration in Subjects With Chronic Kidney Disease Receiving Dialysis

Status:
Completed

Trial end date:
2008-12-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the proportion of subjects sucessfully achieving a mean Hemoglobin greater than or equal to 11 g/dL during the evaluation period following extension from Weekly (QW) to Once Every Other Week (Q2W) Darbepoetin Alfa administraion.

Phase:

Phase 3

Details

Lead Sponsor:

Amgen

Treatments:

Darbepoetin alfa